Sarpogrelate (MCI-9042) 是一种新的特异性5-HT2受体拮抗剂，具有口服活性，Sarpogrelate (MCI-9042) 可以增加血小板聚集，有止血作用，可被用于伯格氏病的研究。

Sarpogrelate (MCI-9042) is a new, specific orally active 5-HT 2 receptor antagonist, Sarpogrelate (MCI-9042) increases platelet aggregation and has hemostasis effect, and can be used for the research of Buerger’s disease [1].

Sarpogrelate (MCI-9042) induces a significant decrease in plasma serotonin (5-HT) concentration and after 2 weeks increases significantly the concentration of whole blood 5-HT. Sarpogrelate (MCI-9042) increases significantly plasma tryptophan concentration after 2 and 4 weeks, and no changes in plasma 5-HIAA concentration. Sarpogrelate (MCI-9042) also has a tendency to increase the concentration of whole blood tryptophan concentration, did not show significant changes in platelet aggregation induced by ADP and collagen. Sarpogrelate (MCI-9042) increases significantly platelet aggregation induced by serotonin after 2 weeks [1].

125926-17-2

C24H31NO6

429.513

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years